NCE Discovery and DARA Biosciences Join Forces to Develop New Therapies
News Dec 06, 2006
DARA BioSciences discovers and develops small molecule treatments for metabolic and CNS diseases and, under the terms of the agreement, will have access to NCED's full range of medicinal chemistry expertise, initially to address two specific drug targets.
"This collaboration is another prime example of NCE Discovery's successful operations as a service provider in the US pharmaceutical market," said Chris Sharman, NCED's CEO.
"We welcome the opportunity to work with the team at DARA BioSciences to speed up the discovery and development of important new medicines."
John Didsbury, Chief Scientific Officer at DARA BioSciences, commented: “We are looking forward to working with NCED and believe that the medicinal chemistry capabilities it brings to the collaboration will help tremendously with our development program of potential new therapies."
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE